Data from PIONEER 1 were not included because oral semaglutide was given as monotherapy [12], PIONEER 2 was excluded because all patients randomised to oral semaglutide or comparator were receiving background metformin (and no other background glucose-lowering medication) [13], and PIONEER 6 was excluded because it was a cardiovascular outcomes trial [14]
[DOI] [PMC free article] [PubMed] [Google Scholar] 25.Hernn MA, Robins JM
PubMed Tjokroprawiro A, Murtiwi S, Tjandrawinata RR
The efficacy and safety of this formulation are well demonstrated in clinical application (101)
How Gallbladder Injury Is Diagnosed (Key for Claims) Objective documentation is highly important
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13 , 30753087